NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS

The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR[gamma]t). These compounds prevent, inhibit, or suppress the action of ROR[gamma]t and are therefore useful in the treatment of ROR[gamma]t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 本公开涉及新型式(I)碳环化合物及其药学上可接受的盐，其中R、R、R、R、R、R、R、R、n、m以及p为如本文所定义的，所述化合物具有作为类视色素相关孤儿受体γt(RORγt)的调节剂的活性。这些化合物预防、抑制或阻止RORγt的作用并且因此适用于治疗RORγt介导的疾病、病症、综合征或病状，诸如例如疼痛、炎症、COPD、哮喘、类风湿性关节炎、结肠炎、多发性硬化、牛皮癣、神经变性疾病以及癌症。